Sector News

Health Enterprise East sells spin out to Allergan

November 6, 2015
Life sciences

Health Enterprise East, a provider of business and innovation management services to the NHS and industry, has sold Northwood Medical Innovations to global pharma Allergan for an undisclosed amount.

Founded in 2010 as a spin out of HEE and West Hertfordshire Hospitals NHS Trust, Northwood has developed a minimally invasive pioneering implant technology, earFold, as an alternative to conventional surgery for correcting prominent ears.

The procedure takes just 20 minutes under local anaesthetic as an outpatient, compared to the traditional two hours in general surgery, and overall outcomes are improved with reduced risk of keloid scaring and cartilage damage, less chance of infection, faster recovery times and improved symmetry when both ears are being corrected, according to HEE.

Botox-maker Allergan, which is currently in talks with Pfizer over a potential merger, is intending to commercialise the product widely across Europe, and will continue to explore the regulatory pathways and necessary clinical data requirements for launching the medical device in other countries, including the US.

Revenues from the company’s sale “will be re-invested into ensuring that other pioneering innovations from staff across the NHS are identified, developed and commercialised,” said HEE.

Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.